- Home
- EQ vs SNT Comparison
EQ vs SNT Comparison
Compare EQ & SNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- SNT
- Stock Information
- Founded
- EQ 2017
- SNT 1965
- Country
- EQ United States
- SNT Canada
- Employees
- EQ N/A
- SNT N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- SNT Telecommunications Equipment
- Sector
- EQ Health Care
- SNT Telecommunications
- Exchange
- EQ Nasdaq
- SNT Nasdaq
- Market Cap
- EQ 85.1M
- SNT 95.2M
- IPO Year
- EQ 2018
- SNT 1993
- Fundamental
- Price
- EQ $1.39
- SNT $4.68
- Analyst Decision
- EQ Hold
- SNT
- Analyst Count
- EQ 2
- SNT 0
- Target Price
- EQ $1.00
- SNT N/A
- AVG Volume (30 Days)
- EQ 489.3K
- SNT 59.3K
- Earning Date
- EQ 11-11-2025
- SNT 11-12-2025
- Dividend Yield
- EQ N/A
- SNT N/A
- EPS Growth
- EQ N/A
- SNT N/A
- EPS
- EQ N/A
- SNT 0.22
- Revenue
- EQ $16,553,000.00
- SNT $38,038,000.00
- Revenue This Year
- EQ N/A
- SNT N/A
- Revenue Next Year
- EQ N/A
- SNT N/A
- P/E Ratio
- EQ N/A
- SNT $22.09
- Revenue Growth
- EQ N/A
- SNT 12.79
- 52 Week Low
- EQ $0.27
- SNT $1.50
- 52 Week High
- EQ $2.35
- SNT $5.34
- Technical
- Relative Strength Index (RSI)
- EQ 48.48
- SNT 49.94
- Support Level
- EQ $1.31
- SNT $4.75
- Resistance Level
- EQ $1.58
- SNT $5.05
- Average True Range (ATR)
- EQ 0.13
- SNT 0.28
- MACD
- EQ 0.01
- SNT -0.01
- Stochastic Oscillator
- EQ 48.64
- SNT 45.23
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.